
New Long-Acting Integrase and Capsid Inhibitors Are on the Horizon
Two new HIV antiretrovirals with a high barrier to resistance—a next-generation integrase inhibitor and a capsid inhibitor from ViiV Healthcare—look promising in early studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI …